Skip Navigation
MUSC mobile menu


Hematology/Oncology Division Programs

Blood and Marrow Transplant Program

Director: Michelle Hudspeth MD

The BMT program is fully accredited by FACT (Foundation for Accreditation for Cellular Therapy) and is in the top-third of programs within the Pediatric Blood and Marrow Transplant Consortium (PBMTC). We perform autologous, related allogeneic , unrelated allogeneic, cord blood and haploidentical transplants. While the majority of our transplants are for malignant diseases, we also perform transplants for non-malignant conditions such as sickle cell disease, aplastic anemia, Diamond-Blackfan anemia, and Fanconi’s anemia. We have a full staff of BMT coordinators, a research study nurse, and data managers. We are also a collection center for the National Marrow Donor Program (NMDP) and fellows have an opportunity to participate in these harvests. We participate in clinical trials through the Pediatric Blood and Marrow Transplant Consortium and the Blood and Marrow Transplant Clinical Trials Network, as well as our own investigator initiated trials and other industry and multi-center trials. Fellows also participate in our weekly BMT intake/patient review meetings and our monthly Quality Management Meetings.

Brain Tumor Program

This is a monthly multi-disciplinary clinic involving pediatric neurosurgery, pediatric oncology, radiation oncology, and pediatric neurology. Fellows participate in the pre-clinic case conference where patients are presented and the pathology and radiology scans are reviewed. Fellows are exposed to the multi-disciplinary approach for these patients and gain additional exposure to tumors that do not require chemotherapy treatment.

Children’s Oncology Group Clinical Trial Program

Principal Investigator: Jackie Kraveka, DO

The Children’s Oncology Group (COG) is the world’s premier pediatric cancer research collaborative. This network of more than 200 Hospitals and 5,000 healthcare professionals dedicates their lives to finding answers and sharing results. 90% of children in North America are treated at COG institutions and enrolled on COG clinical trials. COG members have been the primary innovators in new treatments for children with cancer. Our division is a member of COG and has over 40 clinical Phase II and Phase III trials open for patient accrual.

Dr. Kraveka leads the COG clinical trial team and is assisted by our COG research nurse, Betsy Rackoff RN, Assistant CRAs Andre Kadima, and Katherine Williams-Turner. Fellows undergo Miami CITI training regarding the ethical conduct of clinical trials and participate with attending and clinical research staff in verifying eligibility criteria, obtaining informed consent, delivering protocol-prescribed therapy, grading toxicities, and reporting severe adverse events. Fellows also participate in a yearly conference at Hollings Cancer Center regarding the conduct of clinical trials.

FACT (Follow up after Cancer Treatment) Program

This is our comprehensive clinic for long-term survivors that began in 1995. This clinic meets once or twice a month to provide care for the growing population of survivors. The clinic is coordinated by one of our nurse practitioners, Diane Dufour. She is assisted by Sarah Kessler, RN for the scheduling of the various recommended tests and evaluations. We see many children/young adults with a multitude of issues - notably, endocrinopathies, hepatitis C, cataracts, cardiomyopathy, second malignancies, anxiety and other psychological issues. We currently follow patients through college age, up through age 29. We then refer to internal medicine and remain available for consultation. We also provide on-going resources for patients in between visits, when issues arise. Fellows have the opportunity to learn about changing therapies over time and the long-term impact of these treatments.

Hemophilia Clinic

Director Shayla Bergmann, MD

This clinic provides tertiary care services to children with hemophilia. Patients are evaluated by a pediatric hematologist, nurse coordinator, social worker, and physical therapist to develop a multidisciplinary plan of care. A genetic counseling team is also available. Follow-up appointments are made as needed in the hematology clinic, where children are seen by the hematologist and the hematology/oncology clinic nurses.

Sickle Cell Program

Director: Sherron Jackson MD

Dr. Jackson is assisted by 2 nurse practitioners, Mary Johnson who sees patients in the general SCD clinic and acute care SCD patients in the Day Treatment Area, and Debbie Disco who sees the chronic transfusion patients. Lisa Kuisel, RN is the research study nurse.

Active trials over the past 5 years include:

ASSERT: Phase III, Multicenter 52 Week Randomized, Double-blind, Placebo-Controlled Study about the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell Disease who have had Sickle-Related Painful Crises in Preceding 12 Months

ASSERT: Open-Label Extension Study

Baby HUG: Pediatric Hydroxyurea Phase III Clinical Trial (Randomized, Double-Blind, Placebo-Controlled) Trial of Hydroxyurea Therapy in Very Young Children

SWiTCH: Stroke with Transfusions: Changing to Hydroxyurea

Ameliorating Attention Problems in Children with Sickle Cell Disease

STOP II: Optimizing Primary Stroke Prevention.

Fellows also complete rotations with the blood bank, hematopathology, cytogenetics, and radiation oncology.


View MUSC's Facebook page Follow MUSC on Twitter View the MUSC Health Youtube channel Read the MUSC Health blog circle arrow MUSC_TAG_SOLID_1C